Product Details
| Product Name:
SH5-07 |
CAS No.:
1456632-41-9 |
| Purity:
95.54% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | SH5-07 |
| Description | SH5-07 is a hydroxamic acid-based Stat3 inhibitor (IC50: 3.9 μM). |
| Cell Research | Cells are treated with 0-8 μM agent for 24-48 h. For cell cycle profile analysis, cells are harvested and fixed with 70% ice-cold ethanol and stained with propidium iodide (PI). For apoptosis analysis, cells are collected and stained with FITC-Annexin V using the Apoptosis Detection Kit. Both the DNA content of cells and the Annexin V-positive cells are analyzed by the flow cytometer. Cell cycle phase distribution is analyzed using the Cell-Fit program. Data acquisition is gated to exclude cell doublets. |
| Animal Research | Mice are injected subcutaneously in the left flank area with U251MG cells in 200 μL of PBS/Matrigel matrix, or MDA-MB-231 cells in 100 μL of PBS. Mice with tumors of 90-150 mm^3 (MDA-MB-231) or 150 mm^3 (U251MG) are grouped for identical mean tumor sizes, administered 3, 5 or 6 mg/kg SH5-07 via oral gavage daily or tail vein injection every 2 or 3 days, and monitored every 3-7 days. Tumor sizes are measured with calipers and converted to tumor volume. |
| In vitro | SH5-07, a hydroxamic acid analog of BP-1-102, selectively inhibits Stat3 activity in a dose-dependent manner (IC50: 3.9±0.6 μM in vitro), specifically targeting Stat3:Stat3 DNA-binding over Stat1:Stat3, with minimal impact on Stat1:Stat1. By binding to Stat3, it disrupts its interaction with growth factor receptors, thus inhibiting Stat3 phosphorylation. This inhibition leads to reduced expression of Stat3-regulated genes, including Bcl-xL, Bcl-2, c-Myc, Survivin, Cyclin D1, and Mcl-1, following a 24-hour exposure to 5 μM SH5-07, ultimately exerting antitumor effects against cells with constitutively active Stat3. |
| In vivo | Tail vein injection or oral gavage delivery of SH5-07 inhibits the growth of 90-150 mm^3 established subcutaneous mouse xenografts of human glioma (U251MG) and breast (MDA-MB-231) tumors with aberrantly-active Stat3, associated with decreased Mcl-1, c-Myc, and Cyclin D1 expression. No significant changes in body weights, blood cell counts, organ gross anatomy, or signs of toxicity are observed. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (79.92 mM), Sonication is recommended.
H2O : Insoluble
|
| Keywords | Inhibitor | SH5 07 | inhibit | STAT | SH5-07 | SH507 | SH-5-07 |
| Inhibitors Related | Nifuroxazide | Balsalazide sodium hydrate | Fludarabine | Scutellarin | Niclosamide | 2-(1,8-naphthyridin-2-yl)phenol | CASIN | Diosgenin | Niclosamide olamine | Artesunate | Alantolactone | Stattic |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$34.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
|
|
$1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
|
|
$0.00/10mg |
VIP1Y
|
Xian confluore Biological Technology Co., Ltd.
|
2024-04-01 |
United States